Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Blood (2022) 140 (Supplement 1): 1476–1478.

https://doi.org/10.1182/blood-2022-158883

Published: 2022

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2018) 132 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2018-99-116468

Published: 2018

Journal Articles

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Monica Civallero, PhD, Maria Cosenza, MS, Sandra Marmiroli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 5194.

https://doi.org/10.1182/blood.V130.Suppl_1.5194.5194

Published: 2017

Journal Articles

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2017) 130 (Supplement 1): 5201.

https://doi.org/10.1182/blood.V130.Suppl_1.5201.5201

Published: 2017

Journal Articles

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

Maria Cosenza, Monica Civallero, Steven N Quayle, Stefano Sacchi, Samantha Pozzi

Blood (2016) 128 (22): 2772.

https://doi.org/10.1182/blood.V128.22.2772.2772

Published: 2016

Journal Articles

Co-Targeting Jak Signaling Pathway and Histone Deacetylases Produces Synergistic Activity in Haematologic Malignancies Cell Lines

Monica Civallero, Maria Cosenza, Samantha Pozzi, Stefano Sacchi

Blood (2016) 128 (22): 4717.

https://doi.org/10.1182/blood.V128.22.4717.4717

Published: 2016

Journal Articles

Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery

Monica Civallero, Viviana Vergaro, Cinzia Citti, Maria Cosenza, Giuseppe Cannazza, Carlo Parenti, Alessia Bari, Giuseppe Ciccarella, Stefano Sacchi, Samantha Pozzi

Blood (2015) 126 (23): 4851.

https://doi.org/10.1182/blood.V126.23.4851.4851

Published: 2015

Journal Articles

Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines

Maria Cosenza, Monica Civallero, MS, PhD, Samantha Pozzi, MD, Luigi Marcheselli, Stefano Sacchi, MD

Blood (2014) 124 (21): 3124.

https://doi.org/10.1182/blood.V124.21.3124.3124

Published: 2014

Journal Articles

New Targets and Potential Strategy to Enhance the Anticancer Efficacy BKM-120 and BEZ235 in Lymphoma Cell Lines

Monica Civallero, MS, PhD, Maria Cosenza, Stefano Sacchi, MD

Blood (2014) 124 (21): 1773.

https://doi.org/10.1182/blood.V124.21.1773.1773

Published: 2014

Journal Articles

Romidepsin Synergizes with Lenalidomide in T Cell Lymphoma Cell Lines By Increasing Reactive Oxygen Species and Modulating PI3K/AKT and MAPK/ERK Signaling Pathways

Maria Cosenza, Monica Civallero, MS, PhD, Stefania Fiorcari, Samantha Pozzi, MD, Luigi Marcheselli, Stefano Sacchi, MD

Blood (2014) 124 (21): 1778.

https://doi.org/10.1182/blood.V124.21.1778.1778

Published: 2014

Journal Articles

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

Maria Cosenza, MS, Monica Civallero, MS, PhD, Stefania Fiorcari, MS, Samantha Pozzi, MD, Luigi Marcheselli, Eliana Valentina Liardo, MD, Alessia Bari, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 5148.

https://doi.org/10.1182/blood.V122.21.5148.5148

Published: 2013

Journal Articles

In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.

Maria Cosenza, MS, Monica Civallero, MS, PhD, Samantha Pozzi, Alessia Bari, MD, Eliana Valentina Liardo, Stefano Sacchi

Blood (2012) 120 (21): 2754.

https://doi.org/10.1182/blood.V120.21.2754.2754

Published: 2012

Journal Articles

Combination of NVP-BEZ235 and Enzastaurin on B-Cell Lymphoma Cell Lines: An Effective Therapeutic Strategy

Monica Civallero, Maria Cosenza, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 2719.

https://doi.org/10.1182/blood.V118.21.2719.2719

Published: 2011

Journal Articles

Combination of Enzastaurin, a PKC Inhibitor, and Revlimid ® has Synergistic Activity In Non-Hodgkin Lymphoma

Stefano Sacchi, Maria Cosenza, Monica Civallero, Giulia Grisendi, Erika Road, Luigi Marcheselli

Blood (2010) 116 (21): 4905.

https://doi.org/10.1182/blood.V116.21.4905.4905

Published: 2010

Journal Articles

Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell Lines

Stefano Sacchi, Monica Civallero, Maria Cosenza, Giulia Grisendi, Luigi Marcheselli, Antonino Neri, MD

Blood (2008) 112 (11): 4978.

https://doi.org/10.1182/blood.V112.11.4978.4978

Published: 2008

Journal Articles

The Oral PKC-β Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway.

Antonino Neri, MD, Sandra Marmiroli, MD, Pierfrancesco Tassone, MD, Luigia Lombardi, BS, Lucia Nobili, BS, Donata Verdelli, BS, Monica Civallero, BS, Maria Cosenza, BS, Jessika Bertacchini, BS, Massimo Federico, MD, Anto De Pol, MD, Giorgio Lambertenghi Deliliers, MD, Stefano Sacchi, MD

Blood (2006) 108 (11): 1371.

https://doi.org/10.1182/blood.V108.11.1371.1371

Published: 2006

NARROW

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

Co-Targeting Jak Signaling Pathway and Histone Deacetylases Produces Synergistic Activity in Haematologic Malignancies Cell Lines

Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery

Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines

New Targets and Potential Strategy to Enhance the Anticancer Efficacy BKM-120 and BEZ235 in Lymphoma Cell Lines

Romidepsin Synergizes with Lenalidomide in T Cell Lymphoma Cell Lines By Increasing Reactive Oxygen Species and Modulating PI3K/AKT and MAPK/ERK Signaling Pathways

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.

Combination of NVP-BEZ235 and Enzastaurin on B-Cell Lymphoma Cell Lines: An Effective Therapeutic Strategy

Combination of Enzastaurin, a PKC Inhibitor, and Revlimid ® has Synergistic Activity In Non-Hodgkin Lymphoma

Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell Lines

The Oral PKC-β Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only